Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy - Top-Institutions - MDSpire

Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

  • By

  • Cole Friedes

  • Melanie Berger

  • Lauren Linkowski

  • Casey Hollawell

  • Harper Hubbeling

  • Daniel Alexander

  • Goldie Kurtz

  • Robert A. Lustig

  • Jay F. Dorsey

  • Arati S. Desai

  • Richard E. Phillips

  • Steven Brem

  • Christos Davatzikos

  • MacLean Nasrallah

  • Donald M. O’Rourke

  • Christina Jackson

  • Nduka M. Amankulor

  • Michelle Alonso-Basanta

  • Suyash Mohan

  • Stephen J. Bagley

  • Emily S. Lebow

  • April 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-Oncology
    • Radiation Oncology
    • Molecular Pathology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-Oncology
    • Neurosurgery
    • Molecular Diagnostics

  • #3

    Dana-Farber Cancer Institute / Brigham and Women’s Hospital
    Dana-Farber Cancer Institute / Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Neuro-Oncology
    • Radiation Oncology
    • Translational Research

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-Oncology
    • Neurosurgery
    • Molecular Neurobiology

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neuro-Oncology
    • Radiation Oncology
    • Molecular Pathology

Original Source(s)

Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

  • by Cole Friedes, Melanie Berger, Lauren Linkowski, Casey Hollawell, Harper Hubbeling, Daniel Alexander, Goldie Kurtz, Robert A. Lustig, Jay F. Dorsey, Arati S. Desai, Richard E. Phillips, Steven Brem, Christos Davatzikos, MacLean Nasrallah, Donald M. O’Rourke, Christina Jackson, Nduka M. Amankulor, Michelle Alonso-Basanta, Suyash Mohan, Stephen J. Bagley, Emily S. Lebow

  • April 25, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma